(Q39126141)

English

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

scientific article published on November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

9 September 2017

1 reference

based on heuristic

inferred from title

author name string

Miki Kiyota

1

1 reference

Europe PubMed Central

9 September 2017

Junya Kuroda

2

1 reference

Europe PubMed Central

9 September 2017

Mio Yamamoto-Sugitani

3

1 reference

Europe PubMed Central

9 September 2017

Yuji Shimura

4

1 reference

Europe PubMed Central

9 September 2017

Ryuko Nakayama

5

1 reference

Europe PubMed Central

9 September 2017

Hisao Nagoshi

6

1 reference

Europe PubMed Central

9 September 2017

Shinsuke Mizutani

7

1 reference

Europe PubMed Central

9 September 2017

Yoshiaki Chinen

8

1 reference

Europe PubMed Central

9 September 2017

Nana Sasaki

9

1 reference

Europe PubMed Central

9 September 2017

Natsumi Sakamoto

10

1 reference

Europe PubMed Central

9 September 2017

Tsutomu Kobayashi

11

1 reference

Europe PubMed Central

9 September 2017

Yosuke Matsumoto

12

1 reference

Europe PubMed Central

9 September 2017

Shigeo Horiike

13

1 reference

Europe PubMed Central

9 September 2017

Masafumi Taniwaki

14

1 reference

Europe PubMed Central

9 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2013

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

18

1 reference

Europe PubMed Central

9 September 2017

1437-1446

1 reference

Europe PubMed Central

9 September 2017

11

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s10495-013-0882-y

0 references

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Characterization of cancer stem cells in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

PP2A: the expected tumor suppressor

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Biologically active sphingolipids in cancer pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Involvement of BH3-only proteins in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Lysosomal pathways to cell death and their therapeutic applications.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0882-Y

21 January 2018

Identifiers

10.1007/S10495-013-0882-Y

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39126141&oldid=1808443010"